Comparative Pharmacology
Head-to-head clinical analysis: REOPRO versus TIROFIBAN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REOPRO versus TIROFIBAN HYDROCHLORIDE.
REOPRO vs TIROFIBAN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reopro (abciximab) is a chimeric monoclonal antibody Fab fragment that binds to the glycoprotein IIb/IIIa receptor on activated platelets, thereby inhibiting platelet aggregation by blocking the binding of fibrinogen and von Willebrand factor.
Reversible antagonist of the platelet glycoprotein IIb/IIIa receptor, inhibiting fibrinogen binding and platelet aggregation.
0.25 mg/kg intravenous bolus over 5 minutes, followed by 0.125 mcg/kg/min (maximum 10 mcg/min) continuous intravenous infusion for 12 hours.
0.4 mcg/kg/min IV for 30 minutes, then 0.1 mcg/kg/min IV continuous infusion.
None Documented
None Documented
Terminal half-life approximately 30 minutes (initial phase) with a second phase of about 4 hours due to slow dissociation from platelet glycoprotein IIb/IIIa receptors; clinical effect persists for platelet inhibition up to 24-48 hours after infusion cessation.
Terminal elimination half-life is approximately 2 hours in healthy individuals, but may be prolonged to 4-6 hours in patients with severe renal impairment (CrCl <30 mL/min).
Renal (primarily via proteolytic degradation into small peptides and individual amino acids); <5% excreted unchanged in urine. Fecal elimination negligible.
Renal excretion accounts for approximately 65% of the dose; 25% is eliminated in feces, and the remainder as metabolites. Biliary excretion is minor.
Category C
Category A/B
Glycoprotein IIb/IIIa Inhibitor
Glycoprotein IIb/IIIa Inhibitor